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Pulmonary Exacerbation Score in Cystic Fibrosis Patients:
Reliability and Validity Testing
Fabienne Keller,1 Yann Kernen, MD,2 Sarath C. Ranganathan, MD,3,4,5 and Gaudenz M. Hafen, MD1,2
Background: Lung disease in cystic fibrosis (CF) is characterized by recurrent pulmonary exacerbations (PEs),
but consensus on diagnostic criteria for PE is lacking. The use of a consistent definition of PE as an outcome
measure in CF clinical trials would allow meaningful comparison across centers. The aim of this study was to
assess the reliability and validity of a simplified version of the Seattle Pulmonary Exacerbation Score (SPEX).
Materials and Methods: A cross-sectional observational study with review of case notes was conducted on
pediatric patients with CF in an outpatient setting. Inter-investigator reliability was assessed using the kappa
coefficient of agreement, and intra-investigator reliability was examined following re-evaluation 21 months
after the initial assessment. The validity of the SPEX was analyzed using independent clinical assessment as the
‘‘gold standard.’’ The performance of the original and simplified scores was compared.
Results: Inter- and intra-investigator reliability of SPEX scores were excellent (k= 0.91 and 0.98, respectively).
Validity testing yielded a kappa coefficient of 0.63. The sensitivity and specificity of the SPEX in detecting PE
were 89.4% and 84%, respectively. The SPEX performed as well as the original measure.
Conclusions: The SPEX is objective and repeatable. This quick and simple-to-use measure performed as well
as the original version and is applicable to a real-life pediatric population outside of the context of narrowly
defined clinical parameters. The use of the SPEX to diagnose PE consistently in children with CF is thus
recommended.
Introduction
Apart from chronic decline in respiratory function,lung disease in cystic fibrosis (CF) is characterized by
episodes of recurrent and acute worsening of respiratory
symptoms and signs,1 often referred to as ‘‘pulmonary ex-
acerbations’’ (PEs).2 A variety of insults, including bacterial
and viral illnesses, sinusitis, allergens, and other irritants,
can alter the fragile homeostasis between airway pathogens
and local host defenses, leading to PE.3 PEs are often as-
sociated with a need for treatment with antibiotics, including
hospitalization in some cases. Each PE has a negative im-
pact on 5-year survival equivalent to a 12% reduction in
predicted percent forced expiratory volume in 1 sec
(FEV1%) and on health-related quality of life.
4 PEs are as-
sociated with fragmented sleep5 and increased mortality,6
and are considered to be strong risk factors for morbidity.7 A
number of preventive treatment strategies have been de-
veloped to reduce the frequency and severity of PEs in pa-
tients with CF, and emerging research suggests that PEs play
a large role in the overall decline in lung function, which
may not subsequently return to baseline.8,9 Treatments in-
clude mucolytic agents, physiotherapy and exercise, anti-
biotics, nutritional strategies, anti-inflammatory agents, and
vaccination against common respiratory pathogens.10
Definitions for PEs have been used in numerous clinical
trials evaluating new treatments in CF.11–14 Despite its im-
portance in the clinical course of CF, consensus on the di-
agnostic criteria for PE is lacking. Since a uniform clinical
outcome measure would allow meaningful comparison
across studies or centers in CF clinical trials, and as mo-
dalities of CF treatment are changing and new treatments
are under investigation, the use of a consistent definition of
PE is important.15
This study aimed to test the inter- and intra-investigator
reliability and validity of the Seattle Pulmonary Exacerba-
tion Score (PEX).16 To the authors’ knowledge, the PEX has
been evaluated only in the sample of patients used to con-
struct it. It was created to provide a standardized definition
of PE for use in clinical trials, based only on patients’
clinical status. The PEX was elaborated using patients with
CF aged ‡6 years with FEV1 between 75% and 25% of
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predicted value, positivity for Pseudomonas aeruginosa in
sputum within 6 months before inclusion, and room-air
oximetry values ‡88%. It was developed for a multicentric
randomized phase III trial that controlled for tobramycin
inhalation. After reflection on the scoring system,16 the
author proposed a simplified draft score sheet: the Simpli-
fied Seattle Pulmonary Exacerbation Score (SPEX; pers.
comm.; Table 1). Apart from testing the reliability and va-
lidity of the SPEX in the real-world setting of a pediatric CF
outpatient clinic, as this instrument has not been evaluated
previously, this study also compared its performance with
that of the original PEX. It was hypothesized that the SPEX
would perform as well as the original version, and would be
applicable to a real-life pediatric population outside the
context of narrowly defined clinical parameters.
Materials and Methods
Study subjects
This cross-sectional observational study involved pa-
tients from a single outpatient CF center in the pediatric
department of the University Hospital, Lausanne, Switzer-
land. Patients had CF diagnoses confirmed by two positive
sweat tests (chloride >60mmol/L) or a genotype with two
identifiable CF-causing mutations. All consecutive patients
attending the clinic for a planned or emergency visit during
a 12-month period (1 January–31 December 2008) were
included, with repeat inclusion of some patients who had
several consultations. As the PEX score does not include a
measure of lung function, all patients aged <16 years were
included.
Assessments
The SPEX (Table 1) was completed as part of this study.
Data were collected retrospectively. The SPEX measures the
evolution during the previous 15 days of six items: cough,
sputum, exercise tolerance, absenteeism, appetite, and chest
examination findings (i.e., appearance of new crackles,
rales, or rhonchi). Three points are given for the first four
items, and two points are given for the last two items. PE is
defined as a score of ‡4.
To act as a ‘‘gold standard’’ for validity testing, one CF
physician (G.M.H.) examined all study subjects during
consultations, taking ordinary medical notes as during rou-
tine standard care without filling in the SPEX. As SPEX
items measure classical parameters in patients with CF,
these data should also appear in regular medical records.
Medical records were created using a database (FileMakerª,
Inc.) with a template and space to enter free text describing
case histories and global evaluations. For the assessment of
inter-investigator reliability, two investigators (a medical
student, F.K., and a consultant at the clinic, Y.K.) inde-
pendently completed the SPEX using notes from the clinical
consultation, without final evaluations or treatment deci-
sions. The aim was to determine, based on the medical
notes, whether subjects were experiencing PE. To test intra-
investigator reliability, one investigator (Y.K.) completed
the SPEX 21 months later (February 2011) using the orig-
inal medical notes. Finally, SPEX results were compared
with the clinical conclusions of the examining physician.
The institution’s review board and the Ethics Committee
of the Canton of Vaud, Lausanne, Switzerland, approved the
study protocol. Data were treated anonymously.
Statistical analysis
Inter- and intra-investigator reliability were evaluated
using the kappa coefficient of agreement.17 The coefficient
interpretation structure of Streiner and Norman18 was used:
poor, k < 0.40; fair, k = 0.40–0.59; good, k = 0.60–0.74; and
excellent, j > 0.74. Logistic regression was applied to
identify the SPEX cutoff score (first measure by Y.K.) that
best discriminated between patients with and without PE (as
identified by the ‘‘gold standard’’). For the calculation of the
SPEX cutoff score, only data from patients who were not
taking antibiotics were included. The area under the receiver
operating characteristic (ROC) curve was calculated, with a
value of 1.0 representing 100% sensitivity and specificity. A
subgroup analysis was conducted comparing patients taking
antibiotics at the time of PE assessment with those newly
prescribed antibiotics during consultations. Data were ana-
lyzed using Microsoft Excel 2002 (Microsoft plc, Seattle,
WA) and Stata v13 (StataCorp LP, College Station, TX)
software.
Results
Data from 234 consecutive consultations were included.
The population consisted of 32 patients (13 males) ranging
in age from 2 months to 16 years (median 8.5 years). Pa-
tients with PE were significantly older than those without PE
(Mage = 9.98 years vs. 8.14 years; p = 0.009). Nevertheless,
age had no effect on the probability of having PE, according
to SPEX score. Mean predicted FEV1% was 85.76% (Table
2). For 37 consultations, patients were already on antibiotic
Table 1. Simplified Seattle Pulmonary Exacerbation Score (SPEX)
Modification of symptoms during the last 15 days Yes No
1 Increased cough (frequency and/or severity) over the past 2 weeks 3 0
2 Increased sputum production or chest congestion over the past 2 weeks 3 0
3 Decreased exercise tolerance, increased dyspnea with exertion, or playing less over the past 2 weeks 3 0
4 Missed day care, school, or work in the past 2 weeks due to illness 3 0
5 Decreased appetite over the past 2 weeks 2 0
6 Chest exam: New crackles, rales or rhonchi on auscultation of the chest 2 0
Total score
In the score, six items are assessed by presence or absence of the symptom or physical sign over a 2-week period. Three points are given
for the four first items, and two for the last two items. A PE is defined as a score of ‡4. The modifications from original score are in the
adjunction of day care for absenteeism.
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treatment. One consultation was excluded because insuffi-
cient data were available to complete the SPEX, and two
consultations were excluded because the patients’ sex could
not be identified.
For the SPEX, the ROC curve was 0.91. The ROC curve
data indicated that the probability of experiencing a PE
providing optimal sensitivity and specificity was 0.28, cor-
responding to a score of 4.03. This score had 89.4% sensi-
tivity and 84% specificity, correctly classifying 85.3% of
subjects.
A total of 61 PEs were diagnosed by the physician, and
51 PEs were identified using the SPEX, 40 of which were
also diagnosed by the physician. No PE was identified by
either method for 162 consultations (Table 3). The predic-
tive positive value of the SPEX compared with the physi-
cian’s determination was 78.4%, and the predictive negative
value was 88.5%.
Inter-investigator reliability testing showed discordance in
7/51PE diagnoses (k= 0.91 [95% CI 0.84–0.98]; Table 4).
Intra-investigator reliability showed 97.5% concordance (232/
234 consultations; k= 0.98 [95% CI 0.94–1.00]; Table 5).
To test the validity of the SPEX, concordance was ex-
amined between the determinations of the physician and
investigator 1 (Table 2). The kappa coefficient was 0.63
[95% CI 0.46–0.702]. The validity was higher in the anal-
ysis including only patients not taking antibiotics at the time
of consultation (k = 0.72), with 86.1% sensitivity and 98.1%
specificity.
Discussion
The aim of the current study was to validate a simplified
adaptation of a clinical score used to define the presence or
absence of PE in pediatric patients with CF, and to compare
its performance with that of the original score. The most
discriminative SPEX score was 4, which had 89.4% sensi-
tivity and 84% specificity, correctly classifying 85.3% of
subjects. These values are similar to those for the original
PEX,16 but the intercept parameter of the PEX renders in-
terpretation difficult. The SPEX showed excellent inter- and
intra-investigator reliability (k = 0.91 and 0.98, respective-
ly), good validity (k = 0.63), 89.4% sensitivity, and 84%
specificity. The lower kappa coefficient for validity can be
explained by clinicians’ ability to account for longitudinal
aspects of patients’ courses. For example, a clinician can
consider a brief deterioration 2–3 days prior to a consulta-
tion due to a viral infection in making a decision about the
need for a change of therapy. In contrast, the SPEX is a
cross-sectional measure of changes in symptoms over the
previous 2 weeks that does not account for patients’ global
evolution. This factor probably constitutes a main limitation
of the scoring system.
The predictive positive and negative values of the SPEX
compared with the physician’s determination were better than
reported in other studies.19The validity was higher for patients
whowere not taking antibiotics at the timeof consultation,with
excellent specificity. Numerous other scoring systems are
available. The Fuchs score was used in the DNase study,11,12
the Ramsey score was used in the tobramycin trial,13 the Acute
Respiratory Illness Checklist was used in a phase 2 trial for a
respiratory syncytial virus vaccine,14 and the Respiratory and
Systemic Symptoms Questionnaire was created by Konstan
et al.14 to detect PE regardless of requirement for antibiotic
treatment. Although they are established scores, they lack
validation studies in cohorts of patients other than those in
which they were developed. These scores are based on the
appearance or worsening of signs and symptoms in the lungs
and upper respiratory tract, and some also assess nutrition and
general well-being. Although these instruments are estab-
lished, validation studies conducted with cohorts of patients
other than thosewithwhich theywere developed are lacking.A
simple score based on four symptoms was recently developed
and validated in adult patients.20 These definitions of PE have
been based on empirical data but have not been formally val-
idated.12,13 The signs and symptoms most predictive of PE in
all studies are increased cough, change in sputum volume or
consistency, decreased appetite or weight, and change in re-
spiratory examination findings and rate.21–23 The Fuchs score
was simplified in the Fuchs symptoms,4with criteria similar to
thosemeasured by the PEX,16 but its value in everyday clinical
Table 2. Demographic Table
Number of subjects 32
Males (%) 40.6
Age (years)
Mean 8.33
Median 8.5
Range 0.16–16
FEV1% (>6 years, in % predicted)
Mean 85.76
Median 88
Range 50–124
Number of consultations 234
By males (%) 49.6
FEV1, forced expiratory volume in 1 sec.
Table 3. Validity Between Physician
and Investigator 1 (Y.K.)
Physician/
investigator 1
No
exacerbation Exacerbation Total
No exacerbation 162 11 173
Exacerbation 21 40 61
Total 183 51 234
Kappa 0.63
Table 5. Intra-Investigator Reliability
After 2 Years
Observation 1/2 Score + Score -
Score + 51 0
Score - 2 181
Total 53 181
Kappa 0.98
Table 4. Inter-Investigator Reliability
Investigators 1/2 Score + Score -
Score + 45 1
Score - 6 182
Total 51 183
Kappa 0.91
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practice is limited because it involves the assessment of pul-
monary functionand radiological changes. Pulmonary function
testing limits the age range of patients assessed, and the utility
of chest radiography before every courseof antibiotic treatment
remains a matter of debate.4 The CF Foundation’s clinical
practice guidelines also provide commonly used diagnostic
criteria.24 The diagnosis of PE must be independent of the
physician’s decision on whether to treat it.
Despite the important role of PE in CF, consensus on its
definition in children or adults is lacking.25 A case scenario
study showed that definitions vary within and among cen-
ters, and even at the level of individual clinicians.26 The
present analysis of the SPEX showed good inter- and intra-
investigator correlation, as well as good sensitivity and
specificity. These results confirm that the SPEX defines PE
accurately according to the clinical standards of the authors’
center, in addition to the center in which it was developed.16
The SPEX was chosen for validation, as it is a very simple-
to-use measure that requires no additional examination, such
as lung function testing or radiology. This characteristic is
of particular relevance for the measure’s utilization with
young children or in home settings.
This study has several limitations. First, it was not pos-
sible to complete all SPEX items using the physician’s notes
in some cases. For example, it was not always possible to
determine clearly whether a patient’s appetite had decreased
or varied during the 2 weeks prior to assessment. For
preschool-aged children, absenteeism is best defined (as in
the SPEX) as a parent’s absence from work or the child’s
absence from a daycare facility due to the child’s health. For
that reason, it was added in the SPEX (Table 1). Second, the
use of the CF physician’s clinical judgment as the ‘‘gold
standard’’ for validity testing may be considered a study
limitation. However, the physician was very familiar with
all patients in the authors’ small CF center, optimizing the
odds of PE recognition. In addition, the CF physician, al-
though very familiar with clinical scoring systems, did not
refer to the SPEX before or during the study period. This
does not eliminate the potential bias created by the record-
ing of items believed to be particularly relevant to the SPEX
during consultations. However, the lack of some relevant
information in the notes suggests that this bias was negli-
gible. Third, a study period was defined rather than running
a formal power calculation. The measure also has limita-
tions, as discussed in a report from the EuroCare CF
Working Group: ‘‘the defining score does not always cor-
relate with a change in treatment.’’4 Finally, the study was
conducted at a single center with a small patient cohort.
In conclusion, the present findings suggest that the SPEX
is objective and repeatable. This quick, simple-to-use,
clinically based measure performs as well as the original
PEX and is applicable to a real-life pediatric population
outside the context of narrowly defined clinical parameters.
It requires no additional examination. For these reasons, the
use of the SPEX is recommended in future clinical trials to
identify PE consistently in children with CF.
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